ISCO, CRO Absorption Systems Developing 3D Human Cornea Model to Test Opthalmic Drugs | GenomeWeb
International Stem Cell Corporation and preclinical CRO Absorption Systems last week said that Absorption Systems will use ISCO’s parthenogenetic stem cells, which are derived from unfertilized eggs, to develop a three-dimensional human cornea model in order to help drug makers measure the absorption, distribution, and ocular toxicity of ophthalmic therapeutics.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.